Paxman announces multi centre FDA trial for the prevention of chemotherapy induced alopecia

Paxman, the leading global expert and supplier in scalp cooling for cancer chemotherapy patients, has been granted Investigational Device Exemption (IDE) Approval by the U.S. Food and Drug Administration FDA ahead of a multi-centre, randomized trial of the patented Paxman scalp cooling system for the prevention of chemotherapy induced alopecia.The trial, which was recently approved by the FDA, is the final phase of approval in the United States and paves the way for FDA market approval of the Paxman scalp cooler device, which is already widely used around the world.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news